Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy

被引：27

作者：

Jamil, Muhammad O. ^{[1
]}

Mehta, Amitkumar ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Dept Med, Hematol & Oncol, 1720 2nd Ave South,NP2540N, Birmingham, AL 35294 USA

来源：

EXPERT REVIEW OF HEMATOLOGY | 2016年 / 9卷 / 05期

关键词：

Diffuse large B cell lymphoma; Prognostic marker; lenalidomide; ibrutinib; brentuximab vedotin; bortezomib; POSITRON-EMISSION-TOMOGRAPHY; CHOP-LIKE CHEMOTHERAPY; R-CHOP; MYC REARRANGEMENTS; MOLECULAR SUBTYPES; BURKITT-LYMPHOMA; ELDERLY-PATIENTS; POOR-PROGNOSIS; YOUNG-PATIENTS; OPEN-LABEL;

D O I：

10.1586/17474086.2016.1146584

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma (NHL). DLBCL is clinically, pathologically and molecularly heterogeneous disease. Various clinical, pathological and molecular markers have been developed to characterize the disease. Based on these characterizations, new targeted agents are being investigated to optimize the treatment and improve the outcomes of DLBCL. Enhanced molecular understanding, invention of targeted agents and immunotherapy has opened the doors for improvement in the treatment of DLBCL. In this review, we will discuss various prognostic markers of DLBCL and their potential therapeutic implications.

引用

页码：471 / 477

页数：7

共 50 条

[1] Prognostic markers in diffuse large B-cell lymphoma
Delabie, Jan
LEUKEMIA & LYMPHOMA, 2010, 51 (09) : 1588 - 1589
[2] Biological Prognostic Markers in Diffuse Large B-Cell Lymphoma
Perry, Anamarija M.
Mitrovic, Zdravko
Chan, Wing C.
CANCER CONTROL, 2012, 19 (03) : 214 - 226
[3] Prognostic markers and angiogenesis in diffuse large B-cell lymphoma and follicular lymphoma
Mezei, T.
Gurzu, S.
Raica, M.
Cimpean, A.
Szentirmay, J.
Jung, J.
VIRCHOWS ARCHIV, 2009, 455 : 17 - 18
[4] The search for meaningful prognostic markers in diffuse large B-cell lymphoma
Hsi, ED
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2001, 115 (04) : 481 - 483
[5] Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy
Tomas-Roca, Laura
Rodriguez, Marta
Alonso-Alonso, Ruth
Rodriguez-Pinilla, Socorro M.
Piris, Miguel Angel
HEMATO, 2021, 2 (02): : 281 - 304
[6] PROGNOSTIC IMPACT OF THE DEK ONCOGENE IN DIFFUSE LARGE B-CELL LYMPHOMA
de las Pozas Yesenia, Jimenez
Josefina, Serrano
Marta, Rodriguez
Privette, Lisa M.
Pedrero Sara, Garcia
Raso Arantxa, Garcia
Daniel, Morillo
Alberto, Lopez
Raul, Cordoba
Piris, Miguel A.
Sillero Pilar, Llamas
Garcia Joaquin, Sanchez
Lopez Juana, Serrano
HAEMATOLOGICA, 2021, 106 (10) : 290 - 291
[7] Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology
Winter J.N.
Current Hematologic Malignancy Reports, 2007, 2 (4) : 235 - 241
[8] Refining the prognostic impact of the cell of origin in diffuse large B-cell lymphoma
Balague, O.
Campo, E.
ANNALS OF ONCOLOGY, 2017, 28 (05) : 918 - 920
[9] Prognostic factors in diffuse large B-cell lymphoma
Niitsu, Nozomi
INTERNAL MEDICINE, 2006, 45 (05) : 227 - 228
[10] Prognostic models for diffuse large B-cell lymphoma
Conconi, A
Zucca, E
Roggero, E
Bertoni, F
Bernasconi, A
Mingrone, W
Pedrinis, E
Cavalli, F
HEMATOLOGICAL ONCOLOGY, 2000, 18 (02) : 61 - 73

← 1 2 3 4 5 →